In a significant move aimed at reducing prescription costs for Americans, President Trump unveiled a deal with pharmaceutical company Regeneron. The agreement includes most-favored-nation pricing for prescriptions and promises new gene therapy for rare hearing loss to be provided free of charge in the U.S. Trump emphasized this as the biggest drug price cut in history, celebrating the closing of the first round of drug pricing deals. Regeneron joins other pharmaceutical companies in this initiative, which aims to align U.S. drug prices globally and improve affordability for patients.